Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.

IF 3.4 3区 医学 Q1 RESPIRATORY SYSTEM
Eleni Gkini, Joshua De Soyza, Daniella A Spittle, Paul Robert Ellis, Sarah Tearne, Peymane Adab, Rachel Jordan, Nawar Diar Bakerly, Alice Margaret Turner
{"title":"Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.","authors":"Eleni Gkini, Joshua De Soyza, Daniella A Spittle, Paul Robert Ellis, Sarah Tearne, Peymane Adab, Rachel Jordan, Nawar Diar Bakerly, Alice Margaret Turner","doi":"10.1136/bmjresp-2025-003615","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) patients are encouraged to manage exacerbations (acute exacerbation of COPD (AECOPD)) through self-management (SM) plans. Since only around half of AECOPD are bacterial, and sputum colour correlates with bacterial load, it may help guide antibiotic use. This pragmatic randomised controlled trial (RCT) assessed the safety and effectiveness of using a sputum colour chart in UK primary care.</p><p><strong>Methods: </strong>The multicentre RCT, Colour COPD randomised COPD adults who had ≥2 AECOPD or ≥1 AECOPD hospital admission in the preceding year. The primary objective was to assess the non-inferiority of the Bronkotest sputum colour chart compared with usual care, with hospital admission for AECOPD at 12 months as the primary outcome. Secondary outcomes included second courses of treatment requirement and quality of life (CAT score). Nested substudies examined daily symptoms via e-diaries and sputum culture.</p><p><strong>Results: </strong>115 severe COPD patients (global obstructive lung disease(GOLD) D, 54% Medical Research Council (MRC) 4 or 5, CAT score 24) were randomised. A trend towards more hospital admissions (32% vs 16%, relative risk (RR) 1.95 (0.92-4.18)) and increased antibiotic use within 14 days (34% vs 18%, adjusted relative risk (aRR) 1.80 (0.85-3.79)) was seen in the colour chart group. From 38 sputum substudy patients, 57 samples were received (42 stable, 15 during AECOPD), with 30% containing potentially pathogenic bacterium (PPB). Purulent sputum was more frequent in bronchiectasis, independent of disease state (stable vs exacerbation) or PPB presence, suggesting sputum colour alone does not reliably guide antibiotic use.</p><p><strong>Conclusion: </strong>Under-recruitment precluded definitive conclusions. However, sputum colour is unlikely to be a useful addition to COPD SM in primary care.</p><p><strong>Trial registration number: </strong>The UK's Clinical Study Registry: ISRCTN14955629 (https://doi.org/10.1186/ISRCTN14955629; registration date: 11 Number 2020).</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"12 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517013/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2025-003615","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) patients are encouraged to manage exacerbations (acute exacerbation of COPD (AECOPD)) through self-management (SM) plans. Since only around half of AECOPD are bacterial, and sputum colour correlates with bacterial load, it may help guide antibiotic use. This pragmatic randomised controlled trial (RCT) assessed the safety and effectiveness of using a sputum colour chart in UK primary care.

Methods: The multicentre RCT, Colour COPD randomised COPD adults who had ≥2 AECOPD or ≥1 AECOPD hospital admission in the preceding year. The primary objective was to assess the non-inferiority of the Bronkotest sputum colour chart compared with usual care, with hospital admission for AECOPD at 12 months as the primary outcome. Secondary outcomes included second courses of treatment requirement and quality of life (CAT score). Nested substudies examined daily symptoms via e-diaries and sputum culture.

Results: 115 severe COPD patients (global obstructive lung disease(GOLD) D, 54% Medical Research Council (MRC) 4 or 5, CAT score 24) were randomised. A trend towards more hospital admissions (32% vs 16%, relative risk (RR) 1.95 (0.92-4.18)) and increased antibiotic use within 14 days (34% vs 18%, adjusted relative risk (aRR) 1.80 (0.85-3.79)) was seen in the colour chart group. From 38 sputum substudy patients, 57 samples were received (42 stable, 15 during AECOPD), with 30% containing potentially pathogenic bacterium (PPB). Purulent sputum was more frequent in bronchiectasis, independent of disease state (stable vs exacerbation) or PPB presence, suggesting sputum colour alone does not reliably guide antibiotic use.

Conclusion: Under-recruitment precluded definitive conclusions. However, sputum colour is unlikely to be a useful addition to COPD SM in primary care.

Trial registration number: The UK's Clinical Study Registry: ISRCTN14955629 (https://doi.org/10.1186/ISRCTN14955629; registration date: 11 Number 2020).

痰色图指导慢性阻塞性肺疾病急性加重期抗生素自我治疗:颜色- copd随机对照试验
背景:慢性阻塞性肺疾病(COPD)患者被鼓励通过自我管理(SM)计划来控制急性加重(COPD急性加重(AECOPD))。由于只有大约一半的AECOPD是细菌引起的,而痰的颜色与细菌载量有关,这可能有助于指导抗生素的使用。这项实用的随机对照试验(RCT)评估了在英国初级保健中使用痰色图的安全性和有效性。方法:多中心随机对照试验,彩色慢阻肺随机分组,前一年住院≥2次AECOPD或≥1次AECOPD的慢阻肺成人。主要目的是评估Bronkotest痰色图与常规护理相比的非劣效性,以AECOPD住院12个月为主要结局。次要结局包括第二疗程的治疗要求和生活质量(CAT评分)。巢式亚研究通过电子日记和痰培养检查每日症状。结果:115例重度COPD患者(全球阻塞性肺疾病(GOLD) D, 54%医学研究委员会(MRC) 4或5分,CAT评分24分)被随机分组。在彩色图组中,有更多住院的趋势(32%对16%,相对风险(RR) 1.95(0.92-4.18))和14天内抗生素使用的增加(34%对18%,调整相对风险(aRR) 1.80(0.85-3.79))。从38例痰亚研究患者中,收到57份样本(42份稳定,15份处于AECOPD期间),其中30%含有潜在致病性细菌(PPB)。化脓性痰在支气管扩张中更为常见,与疾病状态(稳定与恶化)或PPB的存在无关,提示仅痰色不能可靠地指导抗生素的使用。结论:招募不足妨碍了明确的结论。然而,在初级保健中,痰色不太可能是COPD SM的有用补充。试验注册号:英国临床研究注册中心:ISRCTN14955629 (https://doi.org/10.1186/ISRCTN14955629;注册日期:2020年11月)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMJ Open Respiratory Research
BMJ Open Respiratory Research RESPIRATORY SYSTEM-
CiteScore
6.60
自引率
2.40%
发文量
95
审稿时长
12 weeks
期刊介绍: BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信